CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 87.41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade BioAtla, Inc. - BCAB CFD

2.98
1.02%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0308%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0137%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 2.95
Open* 2.85
1-Year Change* -4.36%
Day's Range* 2.82 - 2.82
52 wk Range 2.01-26.2
Average Volume (10 days) 0.44097
Average Volume (3 months) 11.9602
Market Cap 416.437
P/E Ratio N/A
Shares Outstanding 37607300
Revenue N/A
EPS -2.73931
Dividend (Yield %) N/A
Beta N/A
Next Earnings Date Feb 27, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jun 29, 2022 2.98 0.09 3.11% 2.89 3.02 2.80
Jun 28, 2022 2.95 -0.03 -1.01% 2.98 3.05 2.85
Jun 27, 2022 3.03 -0.45 -12.93% 3.48 3.49 2.94
Jun 24, 2022 3.50 0.36 11.46% 3.14 3.51 3.01
Jun 23, 2022 2.98 0.04 1.36% 2.94 2.99 2.80
Jun 22, 2022 2.92 0.31 11.88% 2.61 2.99 2.60
Jun 21, 2022 2.71 -0.16 -5.57% 2.87 2.87 2.58
Jun 17, 2022 2.59 0.09 3.60% 2.50 2.73 2.47
Jun 16, 2022 2.45 -0.10 -3.92% 2.55 2.59 2.41
Jun 15, 2022 2.63 0.07 2.73% 2.56 2.71 2.56
Jun 14, 2022 2.65 -0.01 -0.38% 2.66 2.72 2.56
Jun 13, 2022 2.64 -0.17 -6.05% 2.81 2.85 2.55
Jun 10, 2022 2.92 -0.19 -6.11% 3.11 3.25 2.84
Jun 9, 2022 3.01 0.08 2.73% 2.93 3.07 2.89
Jun 8, 2022 3.02 0.07 2.37% 2.95 3.08 2.93
Jun 7, 2022 3.06 0.48 18.60% 2.58 3.07 2.58
Jun 6, 2022 2.66 0.08 3.10% 2.58 2.79 2.58
Jun 3, 2022 2.72 0.43 18.78% 2.29 2.74 2.29
Jun 2, 2022 2.39 0.14 6.22% 2.25 2.45 2.24
Jun 1, 2022 2.31 -0.09 -3.75% 2.40 2.47 2.26

BioAtla, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2018 2019 2020 2021
Total revenue 10.627 5.2 0.429 0.25
Revenue 10.627 5.2 0.429 0.25
Total Operating Expense 38.861 33.468 33.411 96
Selling/General/Admin. Expenses, Total 12.556 7.549 10.595 38.416
Research & Development 26.305 25.919 19.933 58.274
Unusual Expense (Income) 0 0 2.883 -0.69
Operating Income -28.234 -28.268 -32.982 -95.75
Interest Income (Expense), Net Non-Operating -0.74 -1.565 -2.87 0.347
Other, Net -0.005 -0.022 -0.001 0.001
Net Income Before Taxes -28.979 -29.855 -35.853 -95.402
Net Income After Taxes -28.979 -29.855 -35.853 -95.402
Minority Interest 0 0.061 0 0
Net Income Before Extra. Items -28.979 -29.794 -35.853 -95.402
Net Income -28.979 -29.794 -35.853 -95.402
Total Adjustments to Net Income 0.815 1.063
Income Available to Common Excl. Extra. Items -28.164 -28.731 -35.853 -95.402
Income Available to Common Incl. Extra. Items -28.164 -28.731 -35.853 -95.402
Diluted Net Income -28.164 -28.731 -35.853 -95.402
Diluted Weighted Average Shares 32.0886 32.0886 32.0886 34.5612
Diluted EPS Excluding Extraordinary Items -0.87769 -0.89536 -1.11731 -2.76038
Dividends per Share - Common Stock Primary Issue 0 0 0
Diluted Normalized EPS -0.87769 -0.89536 -1.02747 -2.78034
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 0 0.25 0 0 0
Revenue 0 0.25 0 0 0
Total Operating Expense 18.797 30.71 23.005 23.488 24.346
Selling/General/Admin. Expenses, Total 8.374 15.86 7.142 7.04 7.423
Research & Development 10.423 14.85 16.553 16.448 16.923
Operating Income -18.797 -30.46 -23.005 -23.488 -24.346
Interest Income (Expense), Net Non-Operating 0.096 0.079 0.076 0.096 0.085
Net Income Before Taxes -18.701 -30.381 -22.93 -23.39 -24.254
Net Income After Taxes -18.701 -30.381 -22.93 -23.39 -24.254
Net Income Before Extra. Items -18.701 -30.381 -22.93 -23.39 -24.254
Net Income -18.701 -30.381 -22.93 -23.39 -24.254
Income Available to Common Excl. Extra. Items -18.701 -30.381 -22.93 -23.39 -24.254
Income Available to Common Incl. Extra. Items -18.701 -30.381 -22.93 -23.39 -24.254
Diluted Net Income -18.701 -30.381 -22.93 -23.39 -24.254
Diluted Weighted Average Shares 33.6636 33.6789 33.9095 36.9903 37.3224
Diluted EPS Excluding Extraordinary Items -0.55553 -0.90208 -0.67621 -0.63233 -0.64985
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.55553 -0.90208 -0.69656 -0.63233 -0.64985
Unusual Expense (Income) 0 -0.69 0
Other, Net -0.001 0.002 0.007
Minority Interest 0
  • Annual
  • Quarterly
2018 2019 2020 2021
Total Current Assets 12.662 4.507 240.681 247.292
Cash and Short Term Investments 10.863 3.704 238.605 244.979
Cash & Equivalents 10.863 3.704 238.605 244.979
Prepaid Expenses 1.799 0.803 2.076 2.313
Total Assets 16.637 9.336 244.937 254.422
Property/Plant/Equipment, Total - Net 3.878 4.675 4.102 6.976
Property/Plant/Equipment, Total - Gross 5.258 6.889 7.172 11.233
Accumulated Depreciation, Total -1.38 -2.214 -3.07 -4.257
Other Long Term Assets, Total 0.097 0.154 0.154 0.154
Total Current Liabilities 9.196 26.718 32.261 19.813
Accounts Payable 1.961 5.139 2.456 1.179
Payable/Accrued 4.866 4.536 6.808 14.574
Accrued Expenses 1.864 5.55 2.804 4.06
Notes Payable/Short Term Debt 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 9.706 0
Other Current Liabilities, Total 0.505 1.787 20.193 0
Total Liabilities 45.102 65.3 34.963 43.601
Total Long Term Debt 15 8.414 0.682 0
Long Term Debt 15 8.414 0.682 0
Minority Interest 0.019 -0.047 0
Other Liabilities, Total 20.887 30.215 2.02 23.788
Total Equity -28.465 -55.964 209.974 210.821
Redeemable Preferred Stock 89.345 89.345 0 0
Common Stock 0.75 0.75 0.003 0.004
Additional Paid-In Capital 0 2.295 300.888 397.136
Retained Earnings (Accumulated Deficit) -118.56 -148.354 -90.917 -186.319
Total Liabilities & Shareholders’ Equity 16.637 9.336 244.937 254.422
Total Common Shares Outstanding 32.0886 32.0886 33.6636 37.2913
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 224.582 212.331 273.517 247.292 224.019
Cash and Short Term Investments 221.199 207.609 269.925 244.979 219.428
Cash & Equivalents 221.199 207.609 269.925 244.979 219.428
Prepaid Expenses 3.383 4.722 3.592 2.313 4.591
Total Assets 229.087 216.708 277.579 254.422 230.653
Property/Plant/Equipment, Total - Net 4.351 4.223 3.908 6.976 6.48
Property/Plant/Equipment, Total - Gross 7.73 7.919 7.851 11.233 11.041
Accumulated Depreciation, Total -3.379 -3.696 -3.943 -4.257 -4.561
Other Long Term Assets, Total 0.154 0.154 0.154 0.154 0.154
Total Current Liabilities 30.53 36.156 45.227 19.813 17.186
Accounts Payable 2.505 1.283 1.55 1.179 1.199
Payable/Accrued 6.993 12.375 20.381 14.574 13.518
Accrued Expenses 0.833 2.24 3.008 4.06 2.469
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 20.199 20.258 20.288 0
Total Liabilities 33.171 38.685 46.926 43.601 40.6
Total Long Term Debt 0.682 0.682 0 0 0
Long Term Debt 0.682 0.682 0 0
Other Liabilities, Total 1.959 1.847 1.699 23.788 23.414
Total Equity 195.916 178.023 230.653 210.821 190.053
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.003 0.003 0.004 0.004 0.004
Additional Paid-In Capital 305.531 318.019 393.578 397.136 400.622
Retained Earnings (Accumulated Deficit) -109.618 -139.999 -162.929 -186.319 -210.573
Total Liabilities & Shareholders’ Equity 229.087 216.708 277.579 254.422 230.653
Total Common Shares Outstanding 33.6636 33.8074 36.6825 37.2913 37.3833
  • Annual
  • Quarterly
2018 2019 2020 2021
Net income/Starting Line -28.979 -29.855 -35.853 -95.402
Cash From Operating Activities -35.317 -9.645 -36.334 -62.214
Cash From Operating Activities 0.794 0.86 1.008 1.33
Non-Cash Items 3.519 -4.476 1.873 24.434
Changes in Working Capital -10.651 23.826 -3.362 7.424
Cash From Investing Activities -0.988 -1.509 -0.59 -0.924
Capital Expenditures -0.988 -1.509 -0.59 -0.924
Cash From Financing Activities 5.019 3.995 271.825 69.512
Financing Cash Flow Items 0.019 -0.005 200.21 -1.911
Issuance (Retirement) of Stock, Net 0 0 68.183 71.423
Issuance (Retirement) of Debt, Net 5 4 3.432 0
Net Change in Cash -31.286 -7.159 234.901 6.374
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -18.701 -49.082 -72.012 -95.402 -24.254
Cash From Operating Activities -14.994 -28.539 -41.265 -62.214 -25.136
Cash From Operating Activities 0.309 0.636 1.016 1.33 0.313
Non-Cash Items 4.588 16.837 20.403 24.434 3.632
Changes in Working Capital -1.19 3.07 9.328 7.424 -4.827
Cash From Investing Activities -0.501 -0.736 -0.835 -0.924 -0.01
Capital Expenditures -0.501 -0.736 -0.835 -0.924 -0.01
Cash From Financing Activities -1.911 -1.721 73.42 69.512 -0.405
Financing Cash Flow Items -1.911 -1.911 -1.911 -1.911 -0.405
Issuance (Retirement) of Debt, Net 0 0 0 0
Net Change in Cash -17.406 -30.996 31.32 6.374 -25.551
Issuance (Retirement) of Stock, Net 0.19 75.331 71.423
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Soleus Capital Management, L.P. Hedge Fund 7.3747 3400503 137800 2022-09-30 LOW
Short (Jay M) Individual Investor 6.0485 2789003 -4667 2022-11-30 LOW
Cormorant Asset Management, LP Hedge Fund 4.7302 2181115 142900 2022-09-30 LOW
Janus Henderson Investors Investment Advisor/Hedge Fund 4.7163 2174725 -164066 2022-09-30 LOW
Tang Capital Management, LLC Hedge Fund 4.266 1967051 -1405949 2022-09-30 MED
Candriam Belgium S.A. Investment Advisor/Hedge Fund 4.1431 1910406 1528367 2022-09-30 MED
Candriam Luxembourg S.A. Investment Advisor 3.9754 1833059 -17260 2022-10-31 HIGH
Morgan Stanley & Co. LLC Research Firm 3.226 1487545 570223 2022-09-30 MED
HBM Healthcare Investments (Cayman) Ltd. Corporation 3.0954 1427317 -1263552 2021-12-31 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.054 1408232 263597 2022-09-30 LOW
Pfizer Inc Corporation 2.9756 1372052 -866038 2021-12-31 MED
HOOPP Investment Management Pension Fund 1.8655 860200 432700 2022-09-30 HIGH
Eventide Asset Management, LLC Investment Advisor 1.7241 795000 795000 2022-09-30 LOW
Point72 Asset Management, L.P. Hedge Fund 1.6584 764700 764700 2022-09-30 HIGH
Boxer Capital, L.L.C. Hedge Fund 1.4885 686347 0 2022-09-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 1.4307 659696 128989 2022-09-30 LOW
Two Sigma Investments, LP Hedge Fund 1.3362 616123 -287948 2022-09-30 HIGH
Avoro Capital Advisors LLC Investment Advisor/Hedge Fund 1.247 575000 575000 2022-09-30 LOW
Renaissance Technologies LLC Hedge Fund 1.2266 565600 -214800 2022-09-30 HIGH
Altium Capital Management LP Investment Advisor/Hedge Fund 1.1993 553000 553000 2022-09-30 HIGH

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
475000+

Traders

71000+

Active clients monthly

$51000000+

Monthly investing volume

$30000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

BioAtla, Inc. Company profile

About Bioatla Inc

BioAtla, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. Its product candidate includes BA3011, BA3021, BA3071. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL. its second product candidate, BA3021, which is a CAB ADC targeting ROR2. Its third product candidate, BA3071, is a CAB anti-CTLA-4 antibody. The Company also uses its CAB technology to develop bispecific antibodies, which bind both a tumor-specific antigen and a T cell receptor using CAB antigen-binding domains. Its bispecific product candidate includes BA3182, BA3142, EGFR and Nectin-4.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Bioatla Inc revenues decreased 42% to $250K. Net loss increased from $35.9M to $95.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development expense - Balan increase from $16.9M to $53.6M (expense), Stock-based Compensation in SGA increase from $3.9M to $20.4M (expense).

Industry: Biotechnology & Medical Research (NEC)

11085 Torreyana Road
SAN DIEGO
CALIFORNIA 92121
US

Income Statement

People also watch

BTC/USD

16,849.25 Price
-1.090% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 60.00

US100

11,481.60 Price
-0.430% 1D Chg, %
Long position overnight fee -0.0164%
Short position overnight fee 0.0059%
Overnight fee time 22:00 (UTC)
Spread 1.8

Natural Gas

5.75 Price
+7.050% 1D Chg, %
Long position overnight fee 0.0464%
Short position overnight fee -0.0723%
Overnight fee time 22:00 (UTC)
Spread 0.006

XRP/USD

0.38 Price
-2.230% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 0.00332

Still looking for a broker you can trust?

Join the 475.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading